DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR ROSUVASTATIN CALCIUM
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
All Clinical Trials for Rosuvastatin Calcium
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00295373 | Exercise And Rosuvastatin Treatment: Is There an Anti-Inflammatory Synergy? | Unknown status | Purdue University | Phase 4 | 2006-02-01 | The purpose of this study is to determine whether the effects of rosuvastatin treatment and exercise training can be synergistic, with respect to the innate immune receptor TLR4, markers of systemic inflammation, and stimulated production of inflammatory cytokines, in hypercholesterolemic subjects. It is hypothesized that a rosuvastatin and exercise intervention will synergistically lower measured variables, so as to be anti-inflammatory. |
| NCT00300430 | Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia. | Completed | Abbott | Phase 3 | 2006-09-01 | The primary purpose of this study is to test the safety and the effects of using an investigational drug regimen; once daily ABT-335 (Investigational drug) administered in combination with once daily atorvastatin calcium, rosuvastatin calcium or simvastatin in patients with abnormal lipid levels in the blood. |
| NCT00300482 | Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood | Completed | Abbott | Phase 3 | 2006-03-01 | The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335) + rosuvastatin calcium combination therapy with ABT-335 and rosuvastatin calcium monotherapy in subjects with multiple abnormal lipid levels in the blood. |
| NCT00329160 | Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease | Completed | Shionogi | Phase 4 | 2005-10-01 | The primary objective of this study is to evaluate that 76 weeks of treatment with rosuvastatin calcium 2.5-20 mg results in no progression of coronary artery atherosclerotic volume as measured by intravascular ultrasonography (IVUS) imaging in hypercholesterolaemic subjects with coronary heart disease (CHD). |
| NCT00329160 | Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease | Completed | AstraZeneca | Phase 4 | 2005-10-01 | The primary objective of this study is to evaluate that 76 weeks of treatment with rosuvastatin calcium 2.5-20 mg results in no progression of coronary artery atherosclerotic volume as measured by intravascular ultrasonography (IVUS) imaging in hypercholesterolaemic subjects with coronary heart disease (CHD). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Rosuvastatin Calcium
Condition Name
Condition MeSH
Clinical Trial Locations for Rosuvastatin Calcium
Trials by Country
Clinical Trial Progress for Rosuvastatin Calcium
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for Rosuvastatin Calcium
Sponsor Name
